Results 171 to 180 of about 131,242 (269)

Leveraging the ADAM10 prodomain for selective inhibition to enhance recovery after myocardial infarction

British Journal of Pharmacology, EarlyView.
Background and Purpose Inflammation plays a crucial role in the development and progression of numerous acute and chronic diseases such as myocardial infarction (MI) and heart failure. Targeting ADAM proteases, particularly ADAM10, holds promise for fine‐tuning inflammatory responses.
Erik Klapproth, Johanna Marks, Patrick Diaba‐Nuhoho, Sören Grell, Paul Leubauer, Susanne Kämmerer, Johannes R. Soltwedel, Fred Rasmussen, Felix Mejia, Marcia L. Moss, Christopher Prince, Peter Mirtschink, Ben Wielockx, Paul Saftig, Michael Wagner, Kristina Lorenz, Ali El‐Armouche   +16 more
wiley   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists in People With Human Immunodeficiency Virus: An Expanded Meta-Analysis of Metabolic Outcomes

Thomas Barnett
openalex   +2 more sources

Decision letter for "No effects of a six‐week intervention with glucagon‐like peptide‐1 receptor analogue on pancreatic volume and edema in obese men without diabetes"

, 2020

openalex   +1 more source

Deep learning‐enhanced 3D imaging unveils semaglutide impact on cardiac fibrosis

British Journal of Pharmacology, EarlyView.
Background and Purpose Myocardial fibrosis (MF), a hallmark of structural cardiac remodelling, drives disease progression across most forms of heart failure and plays a central role in heart failure with preserved ejection fraction (HFpEF). Despite its clinical relevance, effective treatments remain scarce.
Sheyla Barrado‐Ballestero, Sarah Torp Yttergren, Max Hahn, Marie Biviano Rosenkilde, Ditte Marie Jensen, Michael Christensen, Louise Thisted, Heidi Lindgreen Holmberg, Geoffrey Teixeira, Tor Biering‐Sørensen, Casper Gravesen Salinas, Urmas Roostalu   +11 more
wiley   +1 more source

Mitochondrial movement in pancreatic alpha cells requires Miro2 and is regulated by glucose. [PDF]

J Biol Chem
Ekstrand MH, Nawaz S, Clark A, Hastoy B, Knudsen JG.   +4 more
europepmc   +1 more source

Glucagon‐like peptide‐1 receptor agonists and muscle strength changes in older adults: Risks beyond muscle mass reductions

British Journal of Pharmacology, EarlyView.
Abstract Gastric inhibitory polypeptide (GIP)/Glucagon‐like peptide‐1 (GLP‐1) receptor agonists are increasingly prescribed for the management of obesity and type 2 diabetes, yet research pertinent to their effects on muscle health is limited. Considering the central role of muscle strength as a sarcopenia component, this article summarizes emerging ...
Konstantinos Prokopidis
wiley   +1 more source

Thyroid Cancer Risk in Patients With Type 2 Diabetes Taking Glucagon-Like Peptide 1 Receptor Agonists. [PDF]

OTO Open
Sciscent BY, Eberly HW, Lorenz FJ, Goldrich D, Goyal N, Goldenberg D.   +5 more
europepmc   +1 more source

Prognostic Impact of DPP4 Inhibitors on Systemic Drug Therapy for Advanced Kidney Cancer Patients

Cancer Science, EarlyView.
Treatment with DPP4 inhibitors was identified as a favorable prognostic factor in patients with advanced RCC. A more substantial degree of tumor shrinkage was observed in the subgroup of patients who received tyrosine kinase inhibitors or immune checkpoint inhibitors as first‐line therapy.
Shuhei Kamada, Sachi Kitayama, Ryosuke Yamase, Kazuhiro Ikeda, Wataru Sato, Tomokazu Sazuka, Hideki Takeshita, Shinichi Sakamoto, Akihiro Yano, Kuniko Horie, Tomohiko Ichikawa, Satoru Kawakami, Satoshi Inoue   +12 more
wiley   +1 more source

Validation of Peak Growth Hormone Levels After Clonidine and Glucagon Stimulation Tests in Children With Severe Short Stature. [PDF]

Cureus
Subbiah S, Raja R, Shanmugam D, Palaniappan S, Shanmugam S, Aravind Kumar M.   +5 more
europepmc   +1 more source

Prolonged Somatostatin Receptor 2 Antagonism Enhances Glucagon Response to Hypoglycemia in Male Diabetic Rats.

Endocrinology
D'Souza NC, Aleali N, Shakeri D, Atherley SC, Hoffman EG, Karimi Chahartash S, Javanbakhsh S, Chan O, Liggins RT, Riddell MC.   +9 more
europepmc   +1 more source